Bandingkan Harga & Kinerja Lenox Pasifik Investama Tbk. (LPPS) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Lenox Pasifik Investama Tbk. dan Organon Pharma Indonesia Tbk.: Lenox Pasifik Investama Tbk. diperdagangkan di Rp82 (kapitalisasi pasar 214,82 M, volume 24 jam 1,6 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Lenox Pasifik Investama Tbk. jauh lebih besar — sekitar 2,1× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| LPPS | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 214,82 M | 104,4 M |
Volume | 1,6 jt | — |
Lot | 16,02 rb | — |
Perputaran | 129,47 jt | — |
Harga Rata-rata | 80,8 | — |
Nilai Transaksi | 129,47 jt | — |
Harga Ekuilibrium Indikatif | 82 | — |
Volume Ekuilibrium Indikatif | 286 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Lenox Pasifik Investama Tbk.
PT Lippo Securities Tbk (the Parent Company) was established on June 20, 1989 based on notarial deed No.514 of Misahardi Wilamarta, S.H. The deed of establishment was approved by the Ministry of Justice of the Republic of Indonesia (MOJ) in its decision letter No.C2-6029.HT.01.01TH.89 dated July 6, 1989, and was published in the State of Gazette No.80 Supplement No. 3904 dated October 5, 1990. Its articles of association has been amended several times, most recently by notarial deed No.113 of Ny. Poerbaningsih Asi Warsito, S.H., dated July 30,1999, concerning among others, the adjustments to effect the Regulation No.IX.D.I. On December 20, 1999, the Parent Company submitted a letter to the Chief of the Capital Market Supervisory Board requesting for the revocation of its business license as broker, in connection with the merger of its brokering activities with PT Ciptadana Sekuritas, a subsidiary. This request was approved by the Chief of the Capital Market Supervisory Board based on its decision letter No. 01/PM/2000 dated January 5, 2000.In view of the foregoing, PT Bursa Efek Jakarta in its letter No.S.024/BEJ.ANG/01-2000 dated January 12, 2000 and PT Bursa Efek Surabaya in its letter No. T1-003/AGT/BES/I/2000 dated January 1, 2000, cancelled their Approval Letter on Stock Exchange Membership (Surat Persetujuan Anggota Bursa) issued to the Parent Company effective January 13, 2000 and January 4, 2000, respectively. Accordingly, the Parent Company is required to sell its investments in shares of stock of PT Bursa Efek Jakarta and PT Bursa Efek Surabaya.
Selengkapnya di halaman LPPS →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
